Centocor: Not Yet In RecoveryBy
Although most biotech stocks have been badly beaten up over the past two years, Centocor has managed to stay aloft at around 12, where it has been trading since December. Of late, Centocor seems to have gotten a shot in the arm, which gave analysts reason to raise their estimates. "But watch out," warns investment adviser Evan Sturza. He expects the stock to skid to 7.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.